)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
SynAct Pharma
SynAct Pharma (SYNACT) investor relations material
SynAct Pharma Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary3 Nov, 2026
Executive summary
Q3 2026 advanced Phase 3 planning for resomelagon in rheumatoid arthritis (RA), while a new financing facility and a Brazilian commercial partnership supported development flexibility.
Q3 net loss narrowed YoY and operating expenses declined; cash at quarter-end was SEK 42.4m.
Financial highlights
Q3 net sales were SEK 0; operating expenses were SEK 30.1m, down 15.0% YoY, and net loss was SEK 32.2m versus SEK 35.7m.
Q3 EPS was -SEK 0.57 versus -SEK 0.67 YoY; operating cash flow was -SEK 18.7m versus -SEK 25.8m.
9M operating expenses were SEK 85.2m, down 9.2% YoY; net loss was SEK 79.7m versus SEK 87.9m, and EPS was -SEK 1.44 versus -SEK 1.75.
9M operating cash flow was -SEK 86.2m; cash flow from financing was SEK 88.5m and cash flow for the period was -SEK 11.8m.
R&D costs were SEK 22.2m in Q3 and SEK 60.5m in 9M; R&D was 74% of operating expenses in Q3 and 71% in 9M.
Outlook and guidance
Cash runway extends into Q4 2027; cash and cash equivalents were deemed sufficient to fund the development plan and communicated activities for 12 months forward.
FDA feedback on Phase 3 design and approvability discussions is expected by year-end 2026 or early 2027, followed by consultation with EMA.
RESOVIR-2 Part 1 results are expected in Q4 2026, subject to local regulatory approval of a protocol update; full-study topline is expected in Q2 2027.
No revenue is expected before completion of the resomelagon Phase 2 program, at the earliest in 2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from SynAct Pharma
- A fully funded Phase IIb restart targets resomelagon results by end-2025.SYNACT
Status Update - EXPAND missed its ACR20 endpoint despite a favorable 12-week safety profile.SYNACTStudy Result
- Positive RA data and a fully secured ~SEK 150m rights issue supported AP1189’s next trials.SYNACTInvestor Update
- Advancing phase III-ready inflammation therapies with global partnerships and strong financials.SYNACTInvesting in Life Science 2026
- Advancing first-in-class oral therapy for RA and infectious diseases with strong clinical data.SYNACTCompany presentation
- Resomelagon shows strong efficacy and safety in RA, targeting a large, unmet market with broad potential.SYNACTCompany presentation
- Positive Phase 2b results for resomelagon in RA drive Phase 3 plans and strategic financing.SYNACTQ2 2026
- Resomelagon shows strong clinical promise in RA and viral infections, backed by robust IP and leadership.SYNACTCompany presentation
- Advancing resomelagon for RA and viral infections, targeting major unmet needs with strong IP.SYNACTCompany presentation
Next SynAct Pharma earnings date
Q4 202618 Feb, 2027
SynAct Pharma
Next SynAct Pharma earnings date
Q4 202618 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
SynAct Pharma AB, develops medicines for acute deterioration in inflammatory diseases. The company's lead product, Synacto®, is a mix of three anti-inflammatory protease inhibitors for the treatment of patients who have recently had a heart attack, have re-opened their old heart wounds due to surgery, or are going to undergo procedures in which blood clotting is needed. SynAct Pharma AB is based in Lund, Sweden.